Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Haemonetics (HAE) Equity Ratio (2016 - 2025)

Haemonetics has reported Equity Ratio over the past 16 years, most recently at 0.37 for Q4 2025.

  • Quarterly results put Equity Ratio at 0.37 for Q4 2025, up 2.14% from a year ago — trailing twelve months through Dec 2025 was 0.37 (up 2.14% YoY), and the annual figure for FY2025 was 0.33, down 23.4%.
  • Equity Ratio for Q4 2025 was 0.37 at Haemonetics, up from 0.35 in the prior quarter.
  • Over the last five years, Equity Ratio for HAE hit a ceiling of 0.44 in Q3 2023 and a floor of 0.33 in Q1 2025.
  • Median Equity Ratio over the past 5 years was 0.39 (2022), compared with a mean of 0.39.
  • Biggest five-year swings in Equity Ratio: dropped 26.87% in 2022 and later increased 13.68% in 2023.
  • Haemonetics' Equity Ratio stood at 0.39 in 2021, then grew by 6.56% to 0.41 in 2022, then rose by 3.76% to 0.43 in 2023, then decreased by 16.43% to 0.36 in 2024, then rose by 2.14% to 0.37 in 2025.
  • The last three reported values for Equity Ratio were 0.37 (Q4 2025), 0.35 (Q3 2025), and 0.36 (Q2 2025) per Business Quant data.